First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Relay Therapeutics: the story is balanced — Clinical trial data readouts for lirafugratinib (RLY-4008) in FGFR2+ cholangiocarcinoma and other solid tumors…
★ Analysts see FY2027 revenue reaching $16M — +30.0% growth in a single year.
What Moves the Stock
1Clinical trial data readouts for lirafugratinib (RLY-4008) in FGFR2+ cholangiocarcinoma and other solid tumors - objective response rates above 30% would be viewed positively
2FDA regulatory interactions including Breakthrough Therapy Designation applications, IND clearances for new programs, and potential accelerated approval pathways
3Strategic partnership announcements with big pharma for pipeline programs, particularly upfront payments exceeding $100M
4Competitive developments in FGFR2 and PI3Kα inhibitor space, including approvals or failures of rival programs from Incyte, Novartis, or Taiho
5Cash runway updates and financing activities - equity raises dilute but extend operational timeline
6Collaboration revenue from Genentech partnership (historically ~$20-40M annually, highly variable based on milestone achievements)
7Potential future milestone payments from existing partnerships
8No product revenue currently - pre-commercial stage with pipeline in Phase 1/2 trials
growth/speculative - Attracts biotech specialists, hedge funds with event-driven strategies around clinical catalysts…
High sensitivity to interest rate environment through multiple channels: (1) Valuation multiples compress as risk-free rates rise - biotech…
Watch on earnings: Lirafugratinib (RLY-4008) Phase 2 objective response rate and duration of response in FGFR2-altered cholangiocarcinoma, RLY-2608 Phase 1/2 safety profile and maximum tolerated dose versus competitor PI3Kα inhibitors, Quarterly cash burn rate and ending cash balance to assess runway.
One Sentence Summary:
Relay Therapeutics: the story is balanced — clinical trial data readouts for lirafugratinib (rly-4008) in fgfr2+ cholangiocarcinoma and other solid tumors - objective response rates.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.